Efficacy and safety of ombitasvir/paritaprevir/r and dasabuvir compared to IFN-containing regimens in genotype 1 HCV patients: The MALACHITE-I/II trials
Gregory J Dore, Brian Conway, Yan Luo, Ewa Janczewska, Brygida Knysz, Yan Liu, Adrian Streinu-Cercel, Florin Alexandru Caruntu, Manuela Curescu, Richard Skoien, Wayne Ghesquiere, Wlodzimierz Mazur, Alejandro Soza, Francisco Fuster, Susan Greenbloom, Adriana Motoc, Victoria Arama, David Shaw, Istvan Tornai, Joseph Sasadeusz Show all
Journal of Hepatology | ELSEVIER SCIENCE BV | Published : 2016
The authors would like to express their gratitude to the trial participants, investigators, and coordinators who made this study possible as well as Barbara McGovern, Nancy Shulman, Regis Vilchez, Melissa Cook, Christi Kosogof, Antonis Panagopoulos, Sara Lari, Antigoni Tsoutsou, Barbara Cristofanelli, Travis Yanke, Danielle Grant, Melannie Co, Rajeev Menon, Prajakta Badri, Christine Collins, Tami Pilot-Matias, Rakesh Tripathi, Gretja Schnell, Preethi Krishnan, Thomas Reisch, Jill Beyer, Michelle Irvin, Martin King, Hsiao-Ming Sun, Yan Xie, Jun Sun, Andrea Craze, Kathryn Joiner, and Victoria Mullally of AbbVie for their contributions. This study was funded by AbbVie Inc. Medical writing support was provided by Christine Ratajczak (AbbVie).